Table 2. The PR and PS protein core lists.
| Hub | Degree | Betweenness centrality | Drugs targeting hub | |
|---|---|---|---|---|
| 1 | AXIN2 | 5 | 1346 | |
| 2 | SENP2 | 4 | 1294 | |
| 3 | TOP2A | 8 | 1156.83 | Amsacrine, Valrubicin, Teniposide, Etoposide, Doxorubicin, Idarubicin, Mitoxantrone, Epirubicin, and Podofilox |
| 4 | FZD6 | 3 | 1092.0 | |
| 5 | ERC2 | 4 | 1061 | |
| 6 | NLK | 2 | 1060 | |
| 7 | PCLO | 2 | 912 | |
| 8 | CEP72 | 2 | 870 | |
| 9 | CKAP5 | 2 | 826 | |
| 10 | ABL2 | 4 | 820 | Adenosine triphosphate and Dasatinib |
| 11 | GMPS | 8 | 779.5 | |
| 12 | HDAC2 | 10 | 601 | Vorinostat, Panobinostat, and Romidepsin |
| 13 | HDAC1 | 9 | 391 | Vorinostat, Panobinostat, and Romidepsin |
| 14 | BCL11A | 6 | 372 | |
| 15 | UTY | 8 | 282.5 | |
| 16 | CHD5 | 5 | 281 | Epirubicin (Targets CHD1) |
| 17 | BCL11B | 4 | 225 | |
| 18 | EHMT2 | 6 | 112 | |
| 1 | CAMK2A | 9 | 97.83 | |
| 2 | PLCG1 | 9 | 90 | |
| 3 | GRIN2B | 7 | 58.66 | |
| 4 | PLCG2 | 6 | 22.66 | |
| 5 | GRM5 | 4 | 20 | |
| 6 | GRAP2 | 4 | 20 | |
| 7 | SPTAN1 | 3 | 20 | |
| 8 | CACNA2D3 | 2 | 9.5 | |
| 9 | CACNA1S | 2 | 9.5 | |
| 10 | GRIN2D | 5 | 9.3 |
PR- and PS-specific hubs (red and blue, respectively) are classified according to their degree, betweenness centrality, and drugs targeting them. The hubs with high betweenness centrality are shown in bold and high degree hubs are presented in bold and italic.